Chattem Company Profile

What is the competitive landscape for CHATTEM

CHATTEM has twenty approved drugs.

There are two US patents protecting CHATTEM drugs.

There are sixty-seven patent family members on CHATTEM drugs in forty countries and six supplementary protection certificates in four countries.

Summary for Chattem

International Patents:	67
US Patents:	2
Tradenames:	17
Ingredients:	9
NDAs:	20

Drugs and US Patents for Chattem

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373-001	Jan 24, 2011		OTC	Yes	Yes	8,933,097		Y
Chattem Sanofi	GAVISCON	aluminum hydroxide; magnesium trisilicate	TABLET, CHEWABLE;ORAL	018685-002	Dec 9, 1983		DISCN	Yes	No
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013		OTC	Yes	Yes
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-005	Aug 2, 1996		OTC	Yes	No
Chattem	SELSUN	selenium sulfide	LOTION/SHAMPOO;TOPICAL	007936-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for Chattem

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021909-002	Jan 24, 2011	6,187,791
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996	9,205,059
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996	8,663,680
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996	6,165,497
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996	5,364,630

Paragraph IV (Patent) Challenges for CHATTEM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg		2007-12-17
	Oral Suspension	30 mg/5 mL		2010-01-25
	Oral Solution	0.5 mg/mL		2009-01-14
	Tablets	150 mg		2007-10-30
	Transdermal System	7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs		2014-05-30

International Patents for Chattem Drugs

Country	Patent Number	Estimated Expiration
Germany	602005016802
Japan	5308824
European Patent Office	1768649
Ukraine	89584
Canada	2633086

Supplementary Protection Certificates for Chattem Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3185856	2024C/535	Belgium		PRODUCT NAME: COMBINATIE VAN DOXYLAMINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN PYRIDOXINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE662396 20240321
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
3185856	CR 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	CA 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	LUC00356	Luxembourg		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: 2024030081 20240220

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Chattem
• Chattem Sanofi